TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21183734

Group type: EXPERIMENTAL
Intervention: INV-403 (20 mg/kg per day)
Number of subjects: 0
Study: 19028085

Group type: EXPERIMENTAL
Intervention: Electronic version of the Asthma Quality of Life Questionnaire (AQLQ(S))
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Electronic version of the Asthma Control Questionnaire (ACQ)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Electronic version of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ(S))
Number of subjects: 116

Group type: COMPARATOR
Intervention: Paper version of the Asthma Quality of Life Questionnaire (AQLQ(S))
Number of subjects: 116

Group type: COMPARATOR
Intervention: Paper version of the Asthma Control Questionnaire (ACQ)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Paper version of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ(S))
Number of subjects: 116
Study: 17188581

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting (OPCAB)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Conventional coronary artery bypass grafting (CCAB)
Number of subjects: 330
Study: 16870812

Group type: EXPERIMENTAL
Intervention: Systemic infections (SI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PBMC viral stimulation with cognate myelin Ag
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Blood samples during exacerbations associated with SI
Number of subjects: 60
Study: 12597703

Group type: EXPERIMENTAL
Intervention: 5 mg MPH
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 10 mg MPH
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 20 mg MPH
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 11020741

Group type: EXPERIMENTAL
Intervention: CP‐122,721 200 mg
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: CP‐122,721 100 mg
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Combination therapy (CP‐122,721 200 mg + ondansetron 4 mg)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Ondansetron 4 mg
Number of subjects: 243
Study: 9148198

Group type: EXPERIMENTAL
Intervention: Highly salient (pop out) distractors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unimanual response with right hand
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distractors presented in the same visual halffield as targets
Number of subjects: 0
Study: 1739372

Group type: EXPERIMENTAL
Intervention: MDC (multiple-dose charcoal)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: WBI (whole-bowel irrigation)
Number of subjects: 9

Group type: COMPARATOR
Intervention: CTL (control)
Number of subjects: 9
Study: 6386031

Group type: EXPERIMENTAL
Intervention: Superficial X-ray therapy (100 rad at 50 kV on three occasions at intervals of 21 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo treatment (control hand)
Number of subjects: 24
Study: 31779726

Group type: EXPERIMENTAL
Intervention: Post-service socio-economic factors (absence of debt, stable housing, relationship satisfaction)
Number of subjects: 13856

Group type: EXPERIMENTAL
Intervention: Mental health and alcohol problems (probable PTSD, symptoms of common mental disorder, aggressive behaviour)
Number of subjects: 13856

Group type: COMPARATOR
Intervention: Leaving military service
Number of subjects: 13856
Study: 30583233

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (tVNS)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Sham stimulation of the earlobe
Number of subjects: 94
Study: 28158152

Group type: EXPERIMENTAL
Intervention: Dry needling therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cross tape therapy
Number of subjects: 64
Study: 25187003

Group type: EXPERIMENTAL
Intervention: Cognitive stimulation (CS) - 10 twice weekly meetings focused on a specific cognitive area.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham intervention (CT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive stimulation (CS)
Number of subjects: 0
Study: 24083759

Group type: EXPERIMENTAL
Intervention: Human recombinant EGF-based cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: General supportive skin care (Control)
Number of subjects: 40
Study: 21150465

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m, administered every 3 weeks)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m, administered every 3 weeks)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 150
Study: 18304284

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 403

Group type: COMPARATOR
Intervention: Transdermal E2/NETA (50 microg/140 microg)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 403
Study: 16444068

Group type: EXPERIMENTAL
Intervention: Gonadotrophin releasing hormone agonists (GnRH agonists)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (untreated slowly progressive variants of central precocious puberty)
Number of subjects: 0
Study: 15041351

Group type: EXPERIMENTAL
Intervention: CsA microemulsification formulation (CsA‐ME)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CsA‐ME using C2 monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CsA‐ME
Number of subjects: 0
Study: 11422967

Group type: EXPERIMENTAL
Intervention: Bilateral notches/mean resistance index >= 0.65
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: Bilateral notches/mean resistance index >= 0.55 and unilateral notches/mean resistance index >= 0.65 combined with inhibin-A >= 1.0 multiples of the median
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: Bilateral notches
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: Combined method of uterine artery notch data with inhibin-A
Number of subjects: 689
Study: 9258877

Group type: EXPERIMENTAL
Intervention: Antepartum plasma thrombomodulin levels in preeclamptic women
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Postpartum plasma thrombomodulin levels in preeclamptic women
Number of subjects: 58

Group type: COMPARATOR
Intervention: Antepartum plasma thrombomodulin levels in normotensive controls
Number of subjects: 58

Group type: COMPARATOR
Intervention: Postpartum plasma thrombomodulin levels in normotensive controls
Number of subjects: 58
Study: 8507027

Group type: EXPERIMENTAL
Intervention: 0.05% NaF rinse used once daily
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 0.4% SnF2 gel applied twice daily
Number of subjects: 95

Group type: COMPARATOR
Intervention: 1100 ppm fluoride toothpaste alone
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Comparison between 0.05% NaF rinse and 0.4% SnF2 gel
Number of subjects: 95
Study: 3819572

Group type: EXPERIMENTAL
Intervention: C plus tamoxifen citrate (CT)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: CT plus bacillus Calmette‐Guerin (CTBCG)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and 5‐fluorouracil (C)
Number of subjects: 311
Study: 29980547

Group type: EXPERIMENTAL
Intervention: Culturally adapted physiotherapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual physiotherapy care
Number of subjects: 48
Study: 27263997

Group type: EXPERIMENTAL
Intervention: Prenatal surgery
Number of subjects: 183

Group type: COMPARATOR
Intervention: Postnatal surgery
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Walking independently at 30 months
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Family resources at 12 months
Number of subjects: 183
Study: 25335123

Group type: EXPERIMENTAL
Intervention: High-dose Epoetin beta (30,000 IU on days 1, 2, and 3)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low-dose Epoetin beta (5000 IU on days 1, 3, 5, 7, 9, 11, and 13)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 23532835

Group type: EXPERIMENTAL
Intervention: Existential behavioural therapy (EBT)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Treatment-as-usual (control group)
Number of subjects: 160
Study: 20006168

Group type: EXPERIMENTAL
Intervention: Intranasal desmopressin (300 microg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blood transfusion (fresh frozen plasma 10 mL/kg and/or 1 unit of single donor platelets)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blood transfusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal desmopressin
Number of subjects: 0
Study: 18715755

Group type: EXPERIMENTAL
Intervention: NET+VOC
Number of subjects: 72

Group type: COMPARATOR
Intervention: VOC only
Number of subjects: 72
Study: 16632019

Group type: EXPERIMENTAL
Intervention: Oral fludrocortisone (0.1 mg/d; n = 18)
Number of subjects: 37

Group type: COMPARATOR
Intervention: No treatment (control; n = 19)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Fludrocortisone and control groups
Number of subjects: 37
Study: 12955758

Group type: EXPERIMENTAL
Intervention: Static magnetic field (SMF) combined with antineoplastic chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical control subjects
Number of subjects: 0
Study: 10998482

Group type: EXPERIMENTAL
Intervention: LDL-apheresis (LA) with concomitant simvastatin administration
Number of subjects: 20
Study: 8987046

Group type: EXPERIMENTAL
Intervention: Median nerve SEPs
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Tibial nerve SEPs
Number of subjects: 27

Group type: COMPARATOR
Intervention: MRI abnormalities
Number of subjects: 27

Group type: COMPARATOR
Intervention: Clinical presentation
Number of subjects: 27
Study: 1619204

Group type: EXPERIMENTAL
Intervention: Soy protein beverage
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 10
Study: 6321073

Group type: EXPERIMENTAL
Intervention: Thymostimulin (TS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 21
Study: 30153382

Group type: EXPERIMENTAL
Intervention: Levothyroxine sodium oral solution (4 × 150-μg unit-dose ampules) with water
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Levothyroxine sodium oral solution (4 × 150-μg unit-dose ampules) without water
Number of subjects: 36

Group type: COMPARATOR
Intervention: Levothyroxine sodium soft capsule (4 × 150-μg capsules) with water
Number of subjects: 36
Study: 30161153

Group type: EXPERIMENTAL
Intervention: Verum acupuncture (n = 12)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham laser acupuncture (n = 13)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Verum acupuncture and Sham laser acupuncture
Number of subjects: 25
Study: 27155071

Group type: EXPERIMENTAL
Intervention: Internet-based problem-solving guided self-help intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 0
Study: 25265768

Group type: COMPARATOR
Intervention: Neostigmine 2.5 mg and atropine 1.2 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Neostigmine 2.5 mg, glycopyrrolate 0.2 mg and atropine 0.6 mg
Number of subjects: 51
Study: 22459700

Group type: EXPERIMENTAL
Intervention: Active radiation treatment (890-nm wavelength, 6 sessions of 40 minutes each)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo radiation treatment
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Active radiation treatment (890-nm wavelength)
Number of subjects: 72
Study: 20064223

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulphadoxine-pyrimethamine (SP) implemented in 11 health sub-districts.
Number of subjects: 1350

Group type: COMPARATOR
Intervention: Control group (non-intervention zone) with no IPTi.
Number of subjects: 1350
Study: 18684703

Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 133

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 133

Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 133
Study: 15853199

Group type: EXPERIMENTAL
Intervention: Benzydamine rinse
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 32
Study: 12638102

Group type: EXPERIMENTAL
Intervention: 1 integral
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 6 integral
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 6 wedge
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: burst
Number of subjects: 40
Study: 11025955

Group type: EXPERIMENTAL
Intervention: Propofol-nitrous oxide anesthesia (Group P)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Isoflurane-nitrous oxide anesthesia (Group I)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups (Group P and Group I)
Number of subjects: 28
Study: 9118819

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine 15mg twice daily with dietary support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 0
Study: 1396480

Group type: EXPERIMENTAL
Intervention: Oat bran concentrate (11.2 g of beta-glucan daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 3889933

Group type: EXPERIMENTAL
Intervention: Vitamin E (800 IU/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29502092

Group type: EXPERIMENTAL
Intervention: Chest drainage (tube thoracostomy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 0
Study: 25549202

Group type: EXPERIMENTAL
Intervention: Bolus nasogastric feeding
Number of subjects: 12

Group type: COMPARATOR
Intervention: Continuous nasogastric feeding
Number of subjects: 12
Study: 24910929

Group type: EXPERIMENTAL
Intervention: Real-time biofeedback
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mirror feedback
Number of subjects: 20

Group type: COMPARATOR
Intervention: Raw video feedback
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 20
Study: 22365875

Group type: EXPERIMENTAL
Intervention: Senior resident directed (group B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Attending directed (group A)
Number of subjects: 120
Study: 19523615

Group type: EXPERIMENTAL
Intervention: PCOS patients undergoing controlled ovarian stimulation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (non-PCOS women)
Number of subjects: 80
Study: 18314197

Group type: EXPERIMENTAL
Intervention: Injection drug users (IDUs)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Injection drug users (IDUs) without endocarditis
Number of subjects: 430

Group type: COMPARATOR
Intervention: Nonaddicts
Number of subjects: 430
Study: 15735072

Group type: EXPERIMENTAL
Intervention: Regular margarine (high PHVO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low TFA margarine (low PHVO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Butter (low PHVO but high in naturally occurring TFA)
Number of subjects: 12
Study: 12633131

Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (STS), 20 mg/20 cm², daily for up to 8 weeks
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 289
Study: 11862376

Group type: EXPERIMENTAL
Intervention: Cortisol (hydrocortisone 20 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 10207191

Group type: EXPERIMENTAL
Intervention: Carisolv method (gel treatment)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Traditional drilling
Number of subjects: 137
Study: 7605811

Group type: EXPERIMENTAL
Intervention: Non-ionic contrast medium (Meglium-Ioglicinat, Imeprol)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ionic contrast medium
Number of subjects: 50
Study: 2189417

Group type: EXPERIMENTAL
Intervention: 400 mg/day of ciamexon
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 100 mg/day of ciamexon
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: ciamexon (both dosages)
Number of subjects: 21
Study: 219802

Group type: EXPERIMENTAL
Intervention: Estrogen therapy (large doses of oral conjugated estrogen for three months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (administered for a comparable period)
Number of subjects: 40
Study: 6341417

Group type: EXPERIMENTAL
Intervention: Timolol-Hydrochlorothiazide combination
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Timolol alone
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide alone
Number of subjects: 70
Study: 31593327

Group type: EXPERIMENTAL
Intervention: Exercise three times a week on a stationary bike
Number of subjects: 47
Study: 30502985

Group type: EXPERIMENTAL
Intervention: 100 parts per million denatonium benzoate in sterile water (n = 14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sterile water only (n = 14)
Number of subjects: 28
Study: 26795132

Group type: EXPERIMENTAL
Intervention: Individualized active physiotherapy starting 2 weeks after surgery (n=12)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Transmuscular surgical procedure (n=12)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Usual care (n=13)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Paramedian surgical procedure (n=13)
Number of subjects: 25
Study: 23623825

Group type: EXPERIMENTAL
Intervention: A/T neurofeedback
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: SMR training
Number of subjects: 33

Group type: COMPARATOR
Intervention: Non-intervention controls
Number of subjects: 33
Study: 22723573

Group type: EXPERIMENTAL
Intervention: Teriflunomide 7 mg once daily
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg once daily
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1088
Study: 20465142

Group type: EXPERIMENTAL
Intervention: 4-week NutriActive program
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 19119703

Group type: EXPERIMENTAL
Intervention: Telephonic Disease Management (DM)
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Augmented Disease Management (ADM; DM plus in-home visits by a respiratory therapist)
Number of subjects: 902

Group type: COMPARATOR
Intervention: Traditional Care
Number of subjects: 902
Study: 16120150

Group type: EXPERIMENTAL
Intervention: 595-nm PDL (pulse width 1.5 ms)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 595-nm PDL (pulse width 1.5 ms and 6 ms)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 595-nm PDL (pulse width 20 ms)
Number of subjects: 18
Study: 12636956

Group type: EXPERIMENTAL
Intervention: Clindamycin vaginal cream
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409

Group type: COMPARATOR
Intervention: Term infants
Number of subjects: 409
Study: 10789597

Group type: EXPERIMENTAL
Intervention: Oral granisetron
Number of subjects: 51

Group type: COMPARATOR
Intervention: i.v. granisetron
Number of subjects: 51
Study: 8849763

Group type: EXPERIMENTAL
Intervention: Personal letter signed by GP with a pre‐fixed appointment
Number of subjects: 1170

Group type: EXPERIMENTAL
Intervention: Same as A + letter supporting the study by a well known scientist
Number of subjects: 1170

Group type: EXPERIMENTAL
Intervention: Letter signed by the study coordinator
Number of subjects: 1170

Group type: EXPERIMENTAL
Intervention: One enema, self administered at home two hours before the test
Number of subjects: 1170

Group type: EXPERIMENTAL
Intervention: Two enemas, administered the night before and two hours before the test
Number of subjects: 1170
Study: 1378141

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg once daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nifedipine sustained-release 20 mg twice daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combination treatment of carvedilol and nifedipine SR
Number of subjects: 14

Group type: COMPARATOR
Intervention: Monotherapy (either carvedilol or nifedipine SR)
Number of subjects: 14
Study: 6383098

Group type: EXPERIMENTAL
Intervention: Revisional gastroplasty (gastrogastrostomy)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Conversion to Roux-Y gastric bypass
Number of subjects: 122

Group type: COMPARATOR
Intervention: Primary gastric bypass
Number of subjects: 122
Study: 31310575

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (post hoc analysis)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (post hoc analysis)
Number of subjects: 240
Study: 30030308

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control (no pharmacist-led medication review)
Number of subjects: 157
Study: 26838248

Group type: EXPERIMENTAL
Intervention: Mouth-rinse with G-CSF (150-300ug plus 100ml-500ml normal saline) for at least 7 days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mouth-rinse with G-CSF
Number of subjects: 14
Study: 24733157

Group type: EXPERIMENTAL
Intervention: Acromioplasty
Number of subjects: 95

Group type: COMPARATOR
Intervention: Nonacromioplasty
Number of subjects: 95
Study: 22532515

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5 mg intravenous once yearly
Number of subjects: 7736

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7736
Study: 20796312

Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 4310

Group type: COMPARATOR
Intervention: Comparator regimens
Number of subjects: 4310
Study: 18554876

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 9

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 9
Study: 16026360

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 3700

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3700

Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 3700
Study: 12296617

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day
Number of subjects: 3127

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg/day
Number of subjects: 3127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3127
Study: 9893190

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol dry powder 1600 microg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol dry powder after placebo pretreatment
Number of subjects: 10
Study: 8873523

Group type: EXPERIMENTAL
Intervention: #1 PDS suture placed in a continuous fashion
Number of subjects: 229

Group type: COMPARATOR
Intervention: #1 Ethibond suture placed using an interrupted figure‐eight technique
Number of subjects: 229
Study: 1675877

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (n = 9)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 19